Patents by Inventor Darryle Darwin Schoepp

Darryle Darwin Schoepp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist
    Publication number: 20050192273
    Abstract: The present invention provides for a pharmaceutical composition and methods for treating psychosis comprising the combination or a first component which is an atypical antipsychotic with a second component which is a mGlu2/3 receptor agonist. The present invention also provides for a pharmaceutical composition and method of treating a psychiatric disorder comprising the combination of a first component which is an atypical antipsychotic with a second component which is a compound which allosterically enhances receptor activity for mGlu2 and/or mGlu3.
    Type: Application
    Filed: March 21, 2003
    Publication date: September 1, 2005
    Inventors: Bryan Johnson, Darryle, Darwin Schoepp
  • Potentiators of glutamate receptors
    Patent number: 6800651
    Abstract: The present invention relates to potentiators of metabotropic glutamate receptor function and specifically provides compounds of formula I, compositions thereof and methods of using the same.
    Type: Grant
    Filed: November 20, 2002
    Date of Patent: October 5, 2004
    Assignee: Eli Lilly and Company
    Inventors: Darrell Stephen Coleman, Gunnar Erik Jagdmann, Kirk Willis Johnson, Michael Parvin Johnson, Thomas Hallett Large, James Allen Monn, Darryle Darwin Schoepp, Thomas Charles Britton, Steven Scott Henry, Joseph Patrick Tizzano
  • Potentiators of glutamate receptors
    Publication number: 20040006114
    Abstract: The present invention relates to potentiators of metabotropic glutamate receptor function and specifically provides compounds of formula I, compositions thereof and methods of using the same.
    Type: Application
    Filed: November 20, 2002
    Publication date: January 8, 2004
    Inventors: Darrell Stephen Coleman, Gunnar Erik Jagdmann, Kirk Willis Johnson, Michael Parvin Johnson, Thomas Hallett Large, James Allen Monn, Darryle Darwin Schoepp, David Anthony Barda, Thomas Charles Britton, Bruce Anthony Dressman, Steven Scott Henry, William Joseph Hornback, Joseph Patrick Tizzano, Michael William Fichtner
  • Anxiolytic agents
    Patent number: 5882671
    Abstract: The present invention provides a method of treating anxiety and related disorders using an agonist which acts at negatively coupled cAMP-linked metabotropic glutamate receptors.
    Type: Grant
    Filed: January 21, 1997
    Date of Patent: March 16, 1999
    Assignee: Eli Lilly and Company
    Inventors: David Reed Helton, Mary Jeanne Kallman, James Allen Monn, Darryle Darwin Schoepp, Joseph Patrick Tizzano
  • Excitatory amino acid receptor antagonists
    Patent number: 5843997
    Abstract: The present invention provides novel compounds that affect excitatory amino acid receptors and are useful in the treatment of neurological disorders. This invention also provides synthetic methods for the preparation of the novel compounds.
    Type: Grant
    Filed: April 2, 1996
    Date of Patent: December 1, 1998
    Assignee: Eli Lilly and Company
    Inventors: Lawrence J. Heinz, William H.W. Lunn, Darryle Darwin Schoepp
  • Pharmaceutical compounds for the treatment of CNS diseases
    Patent number: 5739164
    Abstract: Disclosed herein is a method of treating a disease of the central nervous system with a compound of the formula ##STR1## in which m is 0, 1 or 2, n and q are each 0 or 1 to 5, and p is 0 or 1, X is --CO.sub.2 H or tetrazolyl,Y is --CH.dbd.CH--, andZ is(i) phenyl, naphthyl or thienyl, said phenyl, naphthyl and thienyl being optionally substituted,(ii) --CHR.sup.1 R.sup.2 where R.sup.1 and R.sup.2 are each phenyl, naphthyl or thienyl, said phenyl, naphthyl and thienyl being optionally substituted,(iii) .dbd.CR.sup.1 R.sup.2 where R.sup.1 and R.sup.2 are each phenyl, naphthyl or thienyl, said phenyl, naphthyl and thienyl being optionally substituted, or(iv) ##STR2## where r is 0 or 1 to 3 and the phenyl rings are optionally substituted; provided that when Z is phenyl and m is 1, p is 1; and salts and esters thereof.
    Type: Grant
    Filed: September 13, 1996
    Date of Patent: April 14, 1998
    Assignee: Eli Lilly and Company
    Inventors: Jesus Ezquerra Carrera, Almudena Rubio Esteban, Andre Mann, Angele Schoenfelder, Darryle Darwin Schoepp, Concepcion Pedregal Tercero, Camille-Georges Wermuth